Loading clinical trials...

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases | Clinical Trials | Clareo Health

RECRUITINGPHASE1

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

NCT07021209•Grit Biotechnology

View on ClinicalTrials.gov

Summary

This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
•Expected survival period\>12 weeks.
•Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.

Exclusion Criteria

•History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.
•History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.
•Received systemic corticosteroids at a dose of ≥10 mg/day prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.

Locations (1)

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Key Dates

Start Date

January 14, 2025

Primary Completion Date

January 13, 2028

Completion Date

January 13, 2028

Last Updated

September 15, 2025

Enrollment

ESTIMATED participants

Conditions

Neurological Autoimmune Diseases

Interventions

GT719 Injection

BIOLOGICAL

Contacts

Daishi Tian

CONTACT

+8613607178809 tiands@tjh.tjmu.edu.cn

Wei Wang

CONTACT

+86-27-83662640 wwang@tjh.tjmu.edu.cn

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

NCT07275736

Neurological Autoimmune Diseases

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions